CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
marketed topical retinoid +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01461655
NCT01461655Phase 2Completed

Exploratory Study Evaluating the Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris, Using a Split-Face Model

LEO Pharma·interventional·Posted Oct 28, 2011·Updated Mar 10, 2025

In Brief

A Phase 2 clinical trial evaluating marketed topical retinoid, marketed topical NSAID, and 1 other intervention for Acne Vulgaris. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The aim of this proof of principle study is to evaluate efficacy and safety of the sequential application of two marketed products for the treatment of acne vulgaris, using the Split-Face model

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 28, 2011
Enrollment StartNov 1, 2011
Primary CompletionApr 1, 2012
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.7 years ago

Interventions

marketed topical retinoiddrug

once daily application, 4 weeks

marketed topical NSAIDdrug

once daily application, 4 weeks

vehicle geldrug

once daily application, 4 weeks

marketed topical retinoiddrug

once daily application, 4 weeks